[go: up one dir, main page]

GT199700058A - Virosomas cationicos como sistema de transferencia para material genetico. - Google Patents

Virosomas cationicos como sistema de transferencia para material genetico.

Info

Publication number
GT199700058A
GT199700058A GT199700058A GT199700058A GT199700058A GT 199700058 A GT199700058 A GT 199700058A GT 199700058 A GT199700058 A GT 199700058A GT 199700058 A GT199700058 A GT 199700058A GT 199700058 A GT199700058 A GT 199700058A
Authority
GT
Guatemala
Prior art keywords
genetic material
preparation
cells
transfer system
virosomes
Prior art date
Application number
GT199700058A
Other languages
English (en)
Inventor
Klein Peter
Gluck Reinhard
Walti Ernest Rudolf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199700058A publication Critical patent/GT199700058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN VIROSOMA DE CARGA POSITIVA PARA EL SUMINISTRO EFICAZ DE MATERIAL GENETICO A CELULAS EN REPOSO O PROLIFERANTES DE MAMIFEROS IN VITRO E IN VIVO. LA MEMBRANA DEL VIROSOMA CONTIENE LIPIDOS CATIONICOS Y/O POLICATIONICOS, AL MENOS UN PEPTIDO DE FUSION VIRICA Y PREFERENTEMENTE AL MENOS UN MARCADOR CITOESPECIFICO, SELECCIONADO VENTAJOSAMENTE DEL GRUPO FORMADO POR ANTICUERPOS MONOCLONALES, FRAGMENTOS DE ANTICUERPOS F(AB´)2 Y FAB´, CITOQUINAS Y FACTORES DE CRECIMIENTO, PARA LA DETECCION Y UNION SELECTIVA DE CELULAS DIANA. LA INVENCION SE REFIERE ADEMAS A UN METODO PARA LA PREPARACION DE LOS NUEVOS VIROSOMAS Y SUS APLICACIONES, EN ESPECIAL PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DEL CANCER O DE LA LEUCEMIA.
GT199700058A 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico. GT199700058A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08

Publications (1)

Publication Number Publication Date
GT199700058A true GT199700058A (es) 1998-10-29

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199700058A GT199700058A (es) 1996-05-08 1997-05-07 Virosomas cationicos como sistema de transferencia para material genetico.

Country Status (28)

Country Link
US (1) US6210708B1 (es)
EP (1) EP0902682A2 (es)
JP (1) JP2000509404A (es)
KR (1) KR100536983B1 (es)
CN (1) CN1271992C (es)
AR (1) AR007054A1 (es)
AU (1) AU710170B2 (es)
BG (1) BG102880A (es)
BR (1) BR9709224A (es)
CA (1) CA2253561A1 (es)
CO (1) CO4600638A1 (es)
CZ (1) CZ299809B6 (es)
EA (1) EA003130B1 (es)
GT (1) GT199700058A (es)
HR (1) HRP970234B1 (es)
HU (1) HUP9901790A3 (es)
ID (1) ID17934A (es)
NO (1) NO327726B1 (es)
NZ (1) NZ332666A (es)
OA (1) OA10916A (es)
PA (1) PA8429201A1 (es)
PE (1) PE65198A1 (es)
PL (1) PL199201B1 (es)
SK (1) SK152698A3 (es)
SV (1) SV1997000032A (es)
TN (1) TNSN97080A1 (es)
WO (1) WO1997041834A1 (es)
ZA (1) ZA973885B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
EP1011735A1 (en) * 1997-09-08 2000-06-28 Promega Corporation METHOD OF $i(IN VIVO) TRANSFORMATION UTILIZING LIPID VEHICLES
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
JP2003512306A (ja) * 1999-10-08 2003-04-02 ニカ ヘルス プロダクツ リミテッド カチオン性ｄｏｓｐｅｒビロソーム
US6722282B2 (en) * 1999-12-17 2004-04-20 Schott Glas Ignition capsule, which can be inductively activated, for occupant restraint systems, and a test circuit for said ignition capsule
EP1252897A4 (en) * 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
JP2004536607A (ja) * 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
EA008497B1 (ru) * 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
JP4838722B2 (ja) 2003-10-24 2011-12-14 ゲンシア コーポレーション ポリヌクレオチドを送達する方法、及び送達用組成物
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
CN105769931B (zh) 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
US20140335117A1 (en) * 2011-10-07 2014-11-13 Skau Aps Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
WO2018060212A1 (en) 2016-09-27 2018-04-05 Camurus Ab Mixtures and formulations comprising an alkyl ammonium edta salt
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
ATE182791T1 (de) * 1991-05-08 1999-08-15 Schweiz Serum & Impfinst Wiederhergestellte influenza-virosomen mit immunostimulierenden und immunoverstärkenden eigenschaften und diese enthaltende impfstoffe
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1995002698A1 (en) * 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
AU2520595A (en) * 1994-05-31 1995-12-21 Inex Pharmaceuticals Corp. Virosome-mediated intracellular delivery of therapeutic agents
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
CO4600638A1 (es) 1998-05-08
EA199800992A1 (ru) 1999-06-24
CZ299809B6 (cs) 2008-12-03
AU710170B2 (en) 1999-09-16
WO1997041834A1 (en) 1997-11-13
EP0902682A2 (en) 1999-03-24
US6210708B1 (en) 2001-04-03
CA2253561A1 (en) 1997-11-13
NO327726B1 (no) 2009-09-14
NZ332666A (en) 2000-05-26
KR100536983B1 (ko) 2006-06-29
BG102880A (en) 1999-05-31
KR20000010780A (ko) 2000-02-25
TNSN97080A1 (fr) 2005-03-15
NO985137L (no) 1999-01-04
EA003130B1 (ru) 2003-02-27
HUP9901790A2 (hu) 1999-08-30
CN1271992C (zh) 2006-08-30
JP2000509404A (ja) 2000-07-25
PL329853A1 (en) 1999-04-12
CN1225007A (zh) 1999-08-04
SK152698A3 (en) 1999-05-07
NO985137D0 (no) 1998-11-04
AU2776697A (en) 1997-11-26
BR9709224A (pt) 1999-08-10
SV1997000032A (es) 1998-03-27
ZA973885B (en) 1998-11-06
AR007054A1 (es) 1999-10-13
HRP970234B1 (en) 2002-04-30
PA8429201A1 (es) 2000-05-24
PE65198A1 (es) 1998-10-16
ID17934A (id) 1998-02-12
OA10916A (en) 2003-02-21
PL199201B1 (pl) 2008-08-29
HRP970234A2 (en) 1998-06-30
HUP9901790A3 (en) 2010-11-29
CZ361498A3 (cs) 1999-03-17

Similar Documents

Publication Publication Date Title
GT199700058A (es) Virosomas cationicos como sistema de transferencia para material genetico.
Hovanessian et al. The cell-surface-expressed nucleolin is associated with the actin cytoskeleton
ES2070253T3 (es) Ciclohexanoles sustituidos utiles como agentes para el sistema nervioso central.
ATE279942T1 (de) Mehrwertige impstoffzusammensetzung mit gemischten trägern
AR040622A1 (es) Sistemas de policetido sintetasa de acidos grasos poli-insaturados(pufa) y usos de los mismos
TR200201588T2 (tr) Yeni bitki tanım yapıları
BR0110610A (pt) Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
FI963103A7 (fi) Ei-virusvektori
BR0112633A (pt) Método para substituir, translocar e empilhar dna em genomas eucarióticos
ATE240729T1 (de) Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle
PA8583201A1 (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
ES2181752T3 (es) Conjugados de agentes antitumorales de metiltritio y productos intermedios para su sintesis.
AR036272A1 (es) Genes de metiltransferasas y usos de los mismos
ES8202586A1 (es) Un procedimiento para clonar una secuencia de desoxinucleo- tidos
BR0010590A (pt) Emprego de filanto para estimulação objetivada do sistema imunológico
BRPI0409046A (pt) sistemas policetìdio sintase (pks) de ácido graxo poliinsaturado (pufa) e usos dos mesmos
CR6683A (es) Sistema de entrega de quelator de hierro
ES2066038T3 (es) Procedimiento para la produccion de particulas micronizadas biodegradables.
AR026571A1 (es) Genes del musgo de la physcomitrella patens que codifican proteinas que participan en la sintesis de los acidos grasos poliinsaturados y lipidos
DK0904282T3 (da) Hidtil ukendte kationiske cholesterylderivater indeholdende cykliske polære grupper
UY26501A1 (es) Derivados de piperazina sustituidos, su preparación y su empleo como medicamentos
UY26988A1 (es) Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos.
AR067173A1 (es) Metodo para preparar ligadores hidrolizables basados en fmoc
ES2185628T3 (es) Procedimiento para preparar proteinas modificadas.
BR9801085A (pt) Processo para a preparação de moenomicina a.